Polygenic Risk Score and Upgrading in Patients With Prostate Cancer Receiving Active Surveillance

Genitourinary Cancer

Does a Negative Prostate Biopsy Reduce the Risk of Prostate Cancer Reclassification in an Active Surveillance Protocol? An Updated Systematic Review and Meta-Analysis

Prostate

Bahri RA, Mohammadi A, Yar EZ, Rezayat M, Heshmat R, Aghamir SMK

doi: 10.1002/pros.24851

Genitourinary Cancer

Upgrading of Grade Group 1 Prostate Cancer at Prostatectomy: Germline Risk Factors in a Prospective Cohort

Cancer Epidemiol Biomarkers Prev

Liss MA, Zeltser N, Zheng Y, Lopez C, Liu M, Patel Y, Yamaguchi TN, Eng SE, Tian M, Semmes OJ, Lin DW, Brooks JD, Wei JT, Klein EA, Tewari AK, Mosquera JM, Khani F, Robinson BD, Asad M, Troyer DA, Kagan J, Sanda MG, Thompson IM, Boutros PC, Leach RJ

doi: 10.1158/1055-9965.EPI-24-0326

Genitourinary Cancer

Association of Declining Prostate-specific Antigen Levels with Clinical Outcomes in Patients with Metastatic Castration-resistant Prostate Cancer Receiving [(177)Lu]Lu-PSMA-617 in the Phase 3 VISION Trial

Eur Urol

Armstrong AJ, Sartor O, de Bono J, Chi K, Fizazi K, Krause BJ, Herrmann K, Rahbar K, Tagawa ST, Saad F, Beer TM, Wu J, Mirante O, Morris MJ

doi: 10.1016/j.eururo.2024.08.021

Gastrointestinal Cancer

Elective Pelvic Lymph Node Radiation Therapy and the Risk of Death in Patients With Unfavorable-Risk Prostate Cancer: A Postrandomization Analysis

J Clin Oncol

Sayan M, Chen MH, Loffredo M, McMahon E, Moningi S, Orio PF, Nguyen PL, D'Amico AV

doi: 10.1200/JCO.23.02394

Genitourinary Cancer

Combining PSMA-PET and PROMISE to re-define disease stage and risk in patients with prostate cancer: a multicentre retrospective study

Lancet Oncol

Karpinski MJ, Hüsing J, Claassen K, Möller L, Kajüter H, Oesterling F, Grünwald V, Umutlu L, Kleesiek J, Telli T, Merkel-Jens A, Hüsing A, Kesch C, Herrmann K, Eiber M, Hoberück S, Meyer PT, Kind F, Rahbar K, Schäfers M, Stang A, Hadaschik BA, Fendler WP

doi: 10.1016/S1470-2045(24)00326-7

Genitourinary Cancer

Comparative Evaluation of Detection Rates for Clinically Significant Prostate Cancer Using MRI-Targeted Biopsy Alone Versus in Combination With Systematic Biopsies: Development of a Risk-Stratification Scoring System

Prostate

Takahashi T, Nakashima M, Maruno K, Hazama T, Yamada Y, Kikkawa K, Umeoka S, Tamaki M, Ito N

doi: 10.1002/pros.24821

Genitourinary Cancer

Screening for Predictive Factors of Efficacy of Second-Generation Androgen Receptor Axis-Targeted Agents in Patients With High-Risk Metastatic Hormone-Sensitive Prostate Cancer

Prostate

Ueda T, Hayakawa K, Horiguchi G, Murashita J, Shiraishi T, Fujimoto S, Miyashita M, Saito Y, Gabata Y, Sako S, Takahashi H, Fujihara A, Minami T, Yamamoto Y, Okumi M, Hongo F, Okihara K, Fujita K, Ukimura O

doi: 10.1002/pros.24855

Genitourinary Cancer

Targeted Biopsy is Sufficient for Men on Active Surveillance for Early-Stage Prostate Cancer

J Urol

Fakunle MO, Cowan JE, Washington SL 3rd, Shinohara K, Nguyen HG, Carroll PR

doi: 10.1097/JU.0000000000004265

Genitourinary Cancer

Healthy dietary patterns and risk of prostate cancer in men at high genetic risk

Int J Cancer

Zhang Y, Stopsack KH, Song M, Mucci LA, Liu B, Penney KL, Tabung FK, Giovannucci E, Plym A

doi: 10.1002/ijc.34898

Related content

Does a Negative Prostate Biopsy Reduce the Risk of Prostate Cancer Reclassification in an Active Surveillance Protocol? An Updated Systematic Review and Meta-Analysis

Upgrading of Grade Group 1 Prostate Cancer at Prostatectomy: Germline Risk Factors in a Prospective Cohort

Association of Declining Prostate-specific Antigen Levels with Clinical Outcomes in Patients with Metastatic Castration-resistant Prostate Cancer Receiving [(177)Lu]Lu-PSMA-617 in the Phase 3 VISION Trial

Elective Pelvic Lymph Node Radiation Therapy and the Risk of Death in Patients With Unfavorable-Risk Prostate Cancer: A Postrandomization Analysis

Combining PSMA-PET and PROMISE to re-define disease stage and risk in patients with prostate cancer: a multicentre retrospective study

Comparative Evaluation of Detection Rates for Clinically Significant Prostate Cancer Using MRI-Targeted Biopsy Alone Versus in Combination With Systematic Biopsies: Development of a Risk-Stratification Scoring System

Screening for Predictive Factors of Efficacy of Second-Generation Androgen Receptor Axis-Targeted Agents in Patients With High-Risk Metastatic Hormone-Sensitive Prostate Cancer

Targeted Biopsy is Sufficient for Men on Active Surveillance for Early-Stage Prostate Cancer

Healthy dietary patterns and risk of prostate cancer in men at high genetic risk